Aardvark Therapeutics, Inc. Common Stock
$3.81
-4.5%Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.3).
Valuation inputs: P/E -1.3, earnings yield N/A, momentum -4.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -54.0%, ROIC -58.6%).
Profitability stack: net margin 0.0%, ROE -54.0%, ROIC -58.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +9.0%, momentum -4.5%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Aardvark Therapeutics, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Aardvark Therapeutics, Inc. Common Stock Fair Value Envelope
No Revenue Data
AARD has not reported any revenue values in the available annual periods.
Aardvark Therapeutics, Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
AARD has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
AARD has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
AARD has not reported any net profit margin values in the available annual periods.
Aardvark Therapeutics, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Aardvark Therapeutics, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Aardvark Therapeutics, Inc. Common Stock Street Expectations Map
Wall Street analysts project that AARD stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 22.75, with estimates ranging from a low of 3.00 to a high of 47.00.
The consensus 1-year price target stands at 22.75, with estimates ranging from a low of 3.00 to a high of 47.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Aardvark Therapeutics, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $13.87M and sold $78K worth of AARD shares, resulting in $13.79M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
10.0K
144.59K
0
0.00
+145K
+$145K
6-9 Months
33.8K
276.21K
1.2K
5.21K
+271K
+$271K
9-12 Months
1.2M
13.45M
17.2K
72.97K
+13.4M
+$13.38M
Top Buyers
Lee Tien-Li
Director, 10 Percent Owner, Officer: Chief Executive Officer
$6.53M
Sun Nelson
Officer: Chief Financial Officer
$2.46M
Jaiman Manasi
Officer: Chief Medical Officer
$1.43M
Jones Bryan
Officer: Chief Operating Officer
$1.38M
Tong Victor Edward Jr
Director
$689K
Top Sellers
Lee Tien-Li
Director, 10 Percent Owner, Officer: Chief Executive Officer
$78K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $13.79M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
AARD has not reported any dividend yield values in the available annual periods.
aard Dividend History
Learning Layer
Related Guides
Build conviction on AARD by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.